Distinct profile of T cell activation in HIV type 2 compared to HIV type 1 infection: Differential mechanism for immunoprotection

AIDS Research and Human Retroviruses

Volumn 21, Issue 9, 2005, Pages 791-798

  Hanson, Andrea ^a   Sarr, Abdoulaye Dieng ^b   Shea, Amy ^a   Jones, Norman ^a   Mboup, Souleymane ^c   Kanki, Phyllis ^b   Cao, Huyen ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTE COUNT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; LYMPHOCYTE ACTIVATION; PROSPECTIVE STUDIES; PROSTITUTION; SENEGAL; SPECIES SPECIFICITY;

EID: 26444567338     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.791     Document Type: Article

References (48)

1. Marlink R, et al.: Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-1590.
2. Kanki PJ, et al.: Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-946.
3. Kanki P, Sankale J-L, and Mboup S: In: AIDS in Africa (Essex M, Mboup S, Kanki P, Marlink R, and Tlou SD, eds.). Kluwer Academic/Plenum Publisher, New York, 2002, pp. 75-103.
4. Ariyoshi K, et al.: A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa. J Infect Dis 1996;173:245-248.
5. Popper SJ, et al.: Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: Low virus production in vivo. J Virol 2000;74:1554-1557.
6. Popper SJ, et al.: Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999;180:1116-1121.
7. Berry N, et al.: Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol 1998;1:457-468.
8. Kokkotou E, et al.: In vitro correlates of HIV-2-mediated HIV-1 infection. Proc Natl Acad Sci USA 2000;97:6797-6802.
9. Ariyoshi K, et al.: HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS 1995;9:555-559.
10. Jaye A, et al.: No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients. J Infect Dis 2004;189:498-505.
11. Giorgi JV, et al.: Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002;29:346-355.
12. Hazenberg MD, et al.: Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003;17: 1881-1888.
13. Giorgi JV, Hausner MA, and Hultin LE: Detailed immunophenotype of CD8+ memory cytotoxic T-lymphocytes (CTL) against HIV-1 with respect to expression of CD45RA/RO, CD62L, and CD28 antigens. Immunol Lett 1999;66:105-110.
14. Cohen Stuart JW, et al.: The dominant source of CD4+ and CD8+ T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000;25:203-211.
15. Hazenberg MD, Hamann D, Schuitemaker H, and Miedema F: T cell depletion in HIV-1 infection: How CD4+ T cells go out of stock. Nat Immunol 2000;1:285-289.
16. Grossman Z, Meier-Schellersheim M, Sousa AE, Victorino RM, and Paul WE: CD4+ T-cell depletion in HIV infection: Are we closer to understanding the cause? Nat Med 2002;8: 319-323.
17. Anderson RW, Ascher MS, and Sheppard HW: Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: A worst-case dynamic analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:245-252.
18. Blaak H, Boers PH, Schutten M, Van Der Enden ME, and Osterhaus AD: HIV-2-infected individuals with undetectable plasma viremia carry replication-competent virus in peripheral blood lymphocytes. J Acquir Immune Defic Syndr 2004;36:777-782.
19. Shanmugam V, et al.: Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. J Acquir Immune Defic Syndr 2000;24; 257-263.
20. Jaffar S, et al.: Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16;327-332.
21. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, and Victorino RM: CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol 2002;169: 3400-3406.
22. Kanki P, et al.: Prevalence and risk determinants of human immunodeficiency virus type 2 (HIV-2) ancl human immunodeficiency virus type 1 (HIV-1) in West African female prostitutes. Am J Epidemiol 1992;136:895-907.
23. Travers K, et al.: Natural protection against HIV-1 infection provided by HIV-1. Science 1995;268:1612-1615.
24. Ferrari G, et al.: HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. Hum Immunol 2004;65:648-659.
25. Russell ND, Hudgens MG, Ha R, Havenar-Daughton C, and McElrath MJ: Moving to human immunodeficiency virus type 1 vaccine efficacy trials: Defining T cell responses as potential correlates of immunity. J Infect Dis 2003;187:226-242.
26. Cao H, et al.: Cellular immunity to HIV-1 clades: Relevance to HIV-1 vaccine trials in Uganda. J Infect Dis 2000;182:1350-1356.
27. Jones N, et al.: Evaluation of antigen-specific responses using in vitro enriched T cells. J Immunol Methods 2003;274:139-147.
28. Karlsson AC, et al.: Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004;18:981-989.
29. Koesters SA, et al.: Elevation of immune activation in Kenyan women is associated with alterations in immune function: Implications for vaccine development. J Clin Immunol 2004;24:702-709.
30. Gascon RL, et al.: Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion. J Acquir Immune Defic Syndr 2002;30:146-153.
31. Eggena M, et al.: T cell activation in HIV-infected Ugandans: Differential associations with viral load, CD4 depletion, and co-infection. J Infect Dis 2004;191:694-701.
32. Novitsky V, et al.: Association between virus-specific T-cell responses and plasma viral load in human immunodeficiency virus type 1 subtype C infection. J Virol 2003;77:882-890.
33. Frahm N, et al.: Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004;78:2187-2200.
34. Champagne P, et al.: Skewed maturation of memory HIV-specifrc CD8 T lymphocytes. Nature 2001;410:106-111.
35. Harari A, Petitpierre S, Vallelian F, and Pantaleo G: Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: Changes after antiretroviral therapy. Blood 2004;103:966-972.
36. Betts MR, et al.: Analysis of total human immunodeficiency virus (HIV) specific CD4(+) and CD8(+) T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-11991.
37. Schramm B, et al.: Cytopathicity of human immunodeficiency virus type 2 (HIV-2) in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1. J Virol 2000;74: 9594-9600.
38. Bjorling E, et al.: Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993;193:528-530.
39. Bertoletti A, et al.: Cytotoxic T cells from human immunodeficiency virus type-2 infected patients frequently cross-react with different human immunodeficiency virus type 1 clades. J Virol 1998;72:2439-2448.
40. Pinto LA, Covas MJ, and Victorino RM: T-helper cross reactivity to viral recombinant proteins in HIV-2-infected patients. AIDS 1993;7:1389-1391.
41. Cavaleiro R, Sousa AE, Loureiro A, and Victorino RM: Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity. AIDS 2000;14:2679-2686.
42. Shea A, et al.: CCR5 receptor expression is down-regulated in HIV type 2 infection: Implication for viral control and protection. AIDS Res Hum Retroviruses 2004;20:630-635.
43. Orehdi JM, et al.: Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998;178:1279-1287.
44. Koblavi-Deme S, et al.: Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Cote D'Ivoire. AIDS 2004;18:413-419.
45. Ascher MS and Sheppard HW: AIDS as immune system activation: A model for pathogenesis. Clin Exp Immunol 1988;73: 165-167.
46. Grossman Z, Feinberg MB, and Paul WE: Multiple modes of cellular activation and virus transmission in HIV infection: A role for chronically and latently infected cells in sustaining viral replication. Proc Natl Acad Sci USA 1998;95:6314-6319.
47. Grossman Z and Paul WE: The impact of HIV on naive T-cell homeostasis. Nat Med 2000;6:976-977.
48. Zheng NN, et al.: Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. J Virol 2004;78:13934-13942.